Break it Down: American West Metals
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Stockhead's Break it Down brings you today's leading market news in under 90 seconds.
In this episode, host Tylah Tully unpacks American West Metals' (ASX:AW1) latest news, where the company has raised $5.9 million via a single tranche placement, part of a broader $14.4 million dollar funding initiative to advance its Storm Copper Project in Canada.
Watch the video to find out the latest.
Originally published as Break it Down: AW1 locks in another $5.9M to accelerate copper project
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
39 minutes ago
- News.com.au
Health Check: Cochlear's ear-nings downgrade is not what investors wanted to hear
Cochlear downgrades full-year profit expectations, citing sluggish sound processor sales Mesoblast eyes second US drug approval sooner rather than later Who's for a bargain biotech … or three? Cochlear (ASX:COH) is banking on the rollout of new hearing devices to bolster earnings after today downgrading its full-year earnings expectations. The fourth biggest ASX-listed biotech, Cochlear now expects underlying net earnings of $390-400 million, compared with February's guidance at the 'lower end' of $410-430 million. Let's call it a 5% downgrade. Management had expected a single-digit decline in its services revenue – sound processors and the like – but now expects a fall in the high-single digit territory. The problem is that Nucleus 8 sound processor sales grew strongly post launch, but the buzz has abated. Users are unwilling to upgrade to tweaked variants such as the Kanso 'off the ear' processor. 'We continue to work on identifying and connecting with recipients who could benefit from the latest sound processing technology,' the company says. 'These initiatives, combined with the introduction of are expected to lift services revenue in the 2025-26 year.' Meanwhile, sales of the Cochlear implants remain robust and should increase by 10 per in the current year. But growth is weighted to emerging markets. 'Growth in the higher value developed markets has been impacted by slower-than-expected market growth and a small loss of market share in a few countries.' Smart implant launch dulls the pain Not all Cochlear's news was negative. Also today, Cochlear launched its Nucleus Nexa System, 'the world's first and only smart cochlear implant'. The device enables users to upgrade the firmware for both the implant and the related Nucleus 8 Nexa sound processor. Cochlear CEO Dig Howitt says Nexa results from 20 years of research and development. 'Similar to smartphones, the implant firmware can be updated to enable new features and access to future innovations.' After dipping 8% in early trade, Cochlear shares by noon were slightly higher ... so go figure. Buoyant Bioxyne bolsters revenue Bioxyne (ASX:BXN) this morning had a more encouraging update, upping full-year revenue expectations from $25 to $28 million. That's a 200% jump on last year's run rate. Bioxyne sells consumer health products – notably cannabis derived ones such as medicinal 'gummies'. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into producing psychedelic compounds for therapeutic use. The company was granted Australia's first Good Manufacturing Practice licence to produce psilocybin and MDMA ('molly', or ecstasy) Management cites Australian pharmaceutical manufacturing and supply as the key growth driver. "The company is making significant progress in Germany and the UK and will provide a market update shortly." Telix launches second imaging product Telix Pharmaceuticals (ASX:TLX) has launched its second commercial product in the US, also for prostate cancer. The tool, Gozellix, is a kit for preparing an injection of gallium-68 (gozetotide) to detect the tell-tale prostate-specific membrane antigen. The agent is relevant for prostate cancer patients suspected metastases and are candidates for initial definitive therapy. It is also intended for patients with suspected recurrence of prostate cancer based on an elevated serum prostate-specific antigen level. The US Food and Drug Administration (FDA) approved Gozellix in March 2025. The company says Gozellix has a shelf life of up to six hours, which makes it more flexible to use than other products based on the gallium-68 isotope. The company also claims Gozellix is 90% accurate in detecting metastases at the initial stage. In December 2021 the FDA approved Telix's first product, Illucix, which is also gallium-68 based. In calendar 2024 Telix reaped $783 million of revenue from Illucix, 70% higher. US Mesoblast-off for second product? Stem cell therapy developer Mesoblast (ASX:MSB) is confident the FDA will allow accelerated approval of its heart disease drug candidate, Revascor. The agency last December approved Mesoblast's Ryoncil for childhood graft-versus-host disease. That entrenches Ryoncil in the Biotech Hall of Fame as the first and only FDA-approved mesenchymal stromal stem cell product for any indication. Revascor is intended for the much larger market of patients with ischemic chronic heart failure, reduced ejection fraction and inflammation. In the first week of June, Mesoblast held a Type B meeting with FDA to discuss components of a potential filing for marketing approval. 'There was general alignment on items regarding chemistry, manufacturing and controls, potency assays for commercial product release and proposed design and primary endpoint for the confirmatory trial post-approval,' Mesoblast says. 'The company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing.' What's in the brokers' bargain bin? Investors are undervaluing at least three ASX biotech, according to broking analysts. Bell Potter rates Radiopharm Theranostics (ASX:RAD) a buy, citing an 'exceptionally positive outlook'. This follows yesterday's announcement of US Food and Drug Administration fast track approval for its metastatic brain cancer radiotherapy, RAD101. Radiopharm is trialling RAD101 in a 30 patient, phase II effort across five eastern Australian sites. Headline results are due in late 2025 – 'earlier than anticipated'. Bell Potter values the stock at 2.6 cents, compared with yesterday's close of half a cent. Macquarie Equities opines the Monash IVF Group (ASX:MVF) share sell off has been overdone following a second embryo mix-up 'incident'. In a note titled 'bargain hunting' – there's a clue – the firm values the stock at $1.30 a share, implying 100% upside. This is despite the shares recovering 10% this morning after CEO Michael Knaap resigned, leaving CFO Malik Jainudeen to fill the hot seat temporarily. Finally, Morgans values Imricor Medical Systems (ASX:IMR) at $2.28, a 40% increment on the current price. The company has developed the world's first cardiac ablation device that can be guided by magnetic resonance imaging. This week Imricor won European (CE Mark) approval for its Northstar Mapping System, a key component of its offering.
News.com.au
39 minutes ago
- News.com.au
Lunch Wrap: ASX rides oil surge, but Cettire sinks 30pc as luxury demand tanks
ASX holds gains as oil stocks fire up Cettire crashes 26% as luxury demand tanks Monash IVF climbs after CEO steps down The ASX 200 opened higher this morning and by lunchtime AEST it was still clinging onto a 0.20% gain. But while the rest of the market was lethargic, energy stocks were wide awake and charging this morning. Oil jumped over 4% overnight, driven by shrinking US stockpiles and fresh Middle East tension bubbling back to the surface. The US is apparently pulling embassy staff as Iran threatens to hit US bases in the region if nuclear negotiations fall through. The news has lit a fire under the local names this morning, with Woodside Energy Group (ASX:WDS) jumping over 2% and Santos (ASX:STO) tacking on 1.5%. Meanwhile, Trump said last night the US and China had struck a deal, with China expected to send over rare earths and magnets, and in return, the US will let Chinese students back into unis. But markets weren't exactly reassured. 'The uncertainty doesn't help,' said Nick Twidale at AT Global Markets Australia. 'And his overall comments overnight have led to more uncertainty for the market rather than the clarity we were hoping for.' Back home, this is where things stood at about 12:40pm AEST: In the large caps space, Cochlear (ASX:COH) was up 1.5% despite downgrading earnings guidance. It's now expecting between $390m and $400m, down from its earlier forecast, citing softer growth in developed markets. Implants, however, are still tipped to grow 10% this year. AGL Energy (ASX:AGL) dipped 1.5% after confirming it's having an early poke around what to do with its 20% stake in Tilt Renewables. Just 'preliminary investigations", said the company. ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for June 12 : Security Description Last % Volume MktCap ADD Adavale Resource Ltd 0.002 50% 1,261,565 $2,287,279 SFG Seafarms Group Ltd 0.002 50% 2,704,629 $4,836,599 RML Resolution Minerals 0.028 47% 71,723,563 $9,989,950 BLZ Blaze Minerals Ltd 0.004 33% 186,000 $4,700,843 DGR DGR Global Ltd 0.004 33% 1,922,063 $3,131,088 RAN Range International 0.002 33% 250,030 $1,408,935 RLC Reedy Lagoon Corp. 0.002 33% 599,068 $1,165,060 SRN Surefire Rescs NL 0.002 33% 5,580,186 $3,729,668 CDE Codeifai Limited 0.030 30% 2,400,533 $9,900,084 CTN Catalina Resources 0.005 25% 44,131 $9,704,076 EDE Eden Inv Ltd 0.003 25% 1,331,868 $8,219,762 HFY Hubify Ltd 0.010 25% 233,332 $4,089,090 JAV Javelin Minerals Ltd 0.003 25% 753,793 $12,252,298 MEM Memphasys Ltd 0.005 25% 88,464 $7,934,392 MMR Mec Resources 0.005 25% 897,010 $7,399,063 BXN Bioxyne Ltd 0.032 23% 24,279,435 $56,285,547 CLV Clover Corporation 0.500 22% 4,223,205 $68,469,730 SPD Southernpalladium 0.605 21% 210,309 $45,475,000 AHN Athena Resources 0.006 20% 91,054 $11,329,785 GGE Grand Gulf Energy 0.003 20% 714,148 $7,051,062 KPO Kalina Power Limited 0.006 20% 11,576 $14,664,849 JBY James Bay Minerals 0.655 19% 1,019,396 $39,523,424 Medicinal cannabis company Bioxyne (ASX:BXN) has upgraded its full-year revenue forecast to $28m (up from $25m), after a big first half and an even stronger second half expected. BXN says it see big growth locally, as well as in Germany and the UK. It says FY26 should see even more momentum as it pushes further into Europe. Nutritional ingredients supplier Clover Corp (ASX:CLV) expects its FY25 profit to come in around 20% above consensus, with sales also topping the $79 million forecast. It reckons the momentum will carry into FY26, with full results due out in September. Southern Palladium (ASX:SPD) has locked in $8 million from a share placement at 50 cents to help fast-track its Bengwenyama PGM project in South Africa. The raise was led by one of its biggest shareholders, who tipped in $4.6 million. The cash will go towards finalising its Definitive Feasibility Study. Meanwhile, Monash IVF Group (ASX:MVF) tried to hit the reset button. CEO Michael Knaap has stepped down after a second embryo mix-up this week, this time at its Clayton lab. Two bungles in three months is rough going for a company dealing in life's most sensitive business. MVF's shares rose 6% on the news. ASX SMALL CAP LOSERS Here are the worst performing ASX small cap stocks for June 12 : Code Name Price % Change Volume Market Cap ALV Alvo Minerals 0.021 -46% 2,632,293 $5,972,315 OB1 Orbminco Limited 0.001 -33% 2,151,730 $4,796,352 CTT Cettire 0.328 -30% 31,367,200 $177,275,772 HLX Helix Resources 0.002 -25% 2,002,454 $6,728,387 CLG Close Loop 0.052 -22% 2,772,694 $35,633,941 ARC ARC Funds Limited 0.096 -20% 5,500 $6,174,261 TGH Terragen 0.020 -20% 20,000 $12,625,429 1AD Adalta Limited 0.002 -20% 12,000 $2,516,766 AAU Antilles Gold Ltd 0.004 -20% 1,032,221 $11,556,840 OVT Ovanti Limited 0.002 -20% 8,595,935 $6,983,788 RGL Riversgold 0.004 -20% 35,000 $8,418,563 ROG Red Sky Energy. 0.004 -20% 55,000 $27,111,136 TMX Terrain Minerals 0.002 -20% 100,023 $5,621,392 EVE EVE Health Group Ltd 0.033 -18% 1,219,896 $5,274,509 BMO Bastion Minerals 0.003 -17% 4,529,092 $2,710,883 GES Genesis Resources 0.005 -17% 108,549 $4,697,048 ICG Inca Minerals Ltd 0.005 -17% 799,600 $9,458,340 IFG Infocusgroup Hldltd 0.005 -17% 531,286 $1,655,771 TON Triton Min Ltd 0.005 -17% 45,000 $9,410,332 KKO Kinetiko Energy Ltd 0.042 -16% 18,420 $71,629,255 AM5 Antares Metals 0.006 -14% 4,253,015 $3,603,970 AQX Alice Queen Ltd 0.003 -14% 991 $4,373,740 AS2 Askarimetalslimited 0.006 -14% 3,125,202 $2,829,195 Online luxury fashion retailer Cettire (ASX:CTT) crashed after it revealed soft sales, sliding margins, and a nasty FX hit, with US demand dropping off and the June quarter already looking grim. The company said luxury isn't flying like it used to. With cash burning fast and the balance sheet looking thinner by the week, investors reckon a cap raise might be imminent. IN CASE YOU MISSED IT A QMines (ASX:QML) drilling campaign at Develin Creek is rapidly advancing to expand high-grade copper mineralisation and convert inferred resources near Rockhampton in Queensland. Rhythm Biosciences (ASX:RHY) Rhythm Biosciences (ASX:RHY) has published a study in peer-reviewed open access journal PLoS One, validating its colorectal cancer risk assessment model and marking a major step forward in predictive cancer diagnostics. Silver Mines (ASX:SVL) is adding high-prospectivity, low-risk US precious metals exploration assets to complement its Australian portfolio. LAST ORDERS Melody Gold has exercised an option to process surface gold materials at the Horseshoe Metals (ASX:HOR) Horseshoe Lights copper-gold project in Western Australia, providing both tonnage-based payments and a fixed monthly $50,000 from the start of processing. Horseshoe retains its full rights to copper, mixed surface materials, and all subsurface materials at the project, and director Kate Stoney said it was a strategic step forward to capture early cash flow to help expedite the asset's redevelopment as the company ramps up activity. Titanium Sands (ASX:TSL) has confirmed the progress on environmental studies over its Mannar heavy mineral project in Sri Lanka with a recent site visit and advancements in addressing items raised earlier this year. TSL managing director Dr James Searle said the impact assessment was a very real and detailed study of the project area, and that each and every environmental concern would be addressed. 'It is expected the project will generate significant employment opportunities and long-term wealth for the community not just during the project but also ongoing post rehabilitation,' Dr Searle said. Golden Mile Resources (ASX:G88) has added close to $380,000 to the coffers from the ATO through a research and development tax incentive for work over its Quicksilver nickel-cobalt project near Lake Grace in WA in developing laterite processing technology. G88 managing director Damon Dormer welcomed the refund, saying it provides more funding for exploration over its Pearl copper project in Arizona, where it now awaits assays after wrapping up a maiden 10-hole RC campaign.
News.com.au
3 hours ago
- News.com.au
Top 10 at 11: ASX opens higher as energy stocks light the fuse
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.30am, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. The ASX 200 opened 0.25% higher on Thursday, trying to keep the momentum going after scraping a second straight record close on Wednesday. If you're looking for action this morning, look no further than energy. ASX energy stocks are on fire, and it's because the oil price jumped by 4% overnight. Crude prices rose sharply off the back of two big drivers: a bigger-than-expected drawdown in US oil inventories, and fresh jitters in the Middle East. The US is apparently pulling some personnel out of Iraq and other hot zones in the Mid East as tensions with Iran crank up again. Gold stocks are also catching a bid, thanks to a softer-than-expected US inflation read last night. The hearing tech giant trimmed its earnings guidance, but still reckons implant growth will hit 10% for FY25. COH's shares opened 1% lower. WINNERS Code Name Last % Change Volume Market Cap ADD Adavale Resource Ltd 0.002 50% 1,009,043 $2,287,279 MPR Mpower Group Limited 0.011 38% 1,137,874 $2,749,626 RML Resolution Minerals 0.026 37% 26,960,983 $9,989,950 BLZ Blaze Minerals Ltd 0.004 33% 186,000 $4,700,843 RAN Range International 0.002 33% 250,030 $1,408,935 RLC Reedy Lagoon Corp. 0.002 33% 599,068 $1,165,060 SRN Surefire Rescs NL 0.002 33% 252,500 $3,729,668 DVL Dorsavi Ltd 0.021 31% 20,630,136 $11,699,807 BIT Biotron Limited 0.003 25% 311,631 $2,654,492 EDE Eden Inv Ltd 0.003 25% 1,006,868 $8,219,762 In the news... MPower (ASX:MPR) is handing over the keys to almost its entire renewable energy platform, including the Lakeland solar project, in a $19 million deal with climate investor Wollemi. After the sale, it expects to walk away with around $3.8 million in surplus cash. Shareholders will vote on the deal soon, and if it goes through, MPower will rebrand as MPR Australia. Dorsavi (ASX:DVL) has scored exclusive worldwide rights to cutting-edge RRAM tech from NTU Singapore, a deal it said could supercharge its next-gen wearable sensors. The tech offers faster, low-power memory that fits perfectly into dorsaVi's FDA-cleared motion devices. dosaVi now plans to integrate the memory into its sensors for use across healthcare, elite sport, and workplace safety, with an eye on expanding into AI, robotics and IoT. LAGGARDS Code Name Last % Change Volume Market Cap ALV Alvomin 0.020 -48% 1,511,674 $5,972,315 BMO Bastion Minerals 0.002 -33% 2,364,092 $2,710,883 FTC Fintech Chain Ltd 0.002 -33% 2,232,998 $1,952,309 1AD Adalta Limited 0.002 -20% 12,000 $2,516,766 AAU Antilles Gold Ltd 0.004 -20% 1,032,221 $11,556,840 OVT Ovanti Limited 0.002 -20% 8,495,935 $6,983,788 ROG Red Sky Energy. 0.004 -20% 55,000 $27,111,136 ICG Inca Minerals Ltd 0.005 -17% 799,600 $9,458,340 IFG Infocusgroup Hldltd 0.005 -17% 450,000 $1,655,771 AQX Alice Queen Ltd 0.003 -14% 991 $4,373,740 In the news... Alvo Minerals (ASX:ALV) is back trading after locking in $751k from the institutional leg of its entitlement offer, with strong backing from existing investors and its own board. The retail offer, aiming to raise another $811k, is now open and runs until 20 June. The cash will go towards exploration at its copper-zinc Palma Project in Brazil, while Alvo keeps an eye out for other gold and copper assets in the region.
